Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT07788924Phase 4Not yet recruiting
Phase 4, randomised, double-blind trial (2 arms), sponsored by Anderson Advanced Ingredients. Primary endpoint: Changes in the small intestinal (SI) metagenomic profile at 21 days. Planned start Sep 2026; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT07788924.